PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis
Tingyang Wei(Peking University), Linong Ji(Peking University), Zonglin Li(Peking University), Yuteng Yang(Peking University), Chu Lin(Peking University), Wenjia Yang(Peking University), Fang Lv(Liaoning Normal University), Changjie Tie(Peking University), Xiaoling Cai(Peking University)
Cited by 1
Related Papers
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
|Journal of Experimental & Clinical Cancer Research|2022|115